A 12-month, prospective, observational study of ranibizumab in treatment-naïve Taiwanese patients with neovascular age-related macular degeneration: the RACER study

BACKGROUND: The current National Health Insurance scheme in Taiwan reimburses 3 initial plus 4 additional injections of ranibizumab 0.5 mg for eligible patients with neovascular age-related macular degeneration (nAMD). The Ranibizumab AMD Clinical Efficacy in Real-world practice (RACER) study aimed...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Wen-Chuan, Chen, Jiann-Torng, Tsai, Ching-Yao, Wu, Chien-Liang, Cheng, Cheng-Kuo, Shen, Yun-Dun, Tsai, Arslan, Wu, Pei-Chang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7687747/
https://www.ncbi.nlm.nih.gov/pubmed/33238968
http://dx.doi.org/10.1186/s12886-020-01715-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7687747/
https://www.ncbi.nlm.nih.gov/pubmed/33238968
http://dx.doi.org/10.1186/s12886-020-01715-3

Ejemplares similares